Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02688543
Other study ID # RF knee 001
Secondary ID
Status Completed
Phase N/A
First received February 18, 2016
Last updated February 22, 2016
Start date March 2013
Est. completion date January 2016

Study information

Verified date February 2016
Source Hospital General de Jerez de la Frontera
Contact n/a
Is FDA regulated No
Health authority Spain: Comité Ético de Investigación Clínica
Study type Interventional

Clinical Trial Summary

Pharmacological treatment of pain due to osteoarthritis of the knee often proves to be inadequate and/or cause intolerable side effects. Arthroplasty of the knee may offer a solution, but waiting lists may be long or certain patients may not be apt for a surgical intervention. Therefore an alternative pain treatment that is effective and has little side effects allowing to offer pain relief to those difficult to manage patients would be an added value in the therapeutic options.

We studies the short and long-term effects of radio frequency treatment of the genicular nerves in patients with severe pain due to osteoarthritis of the knee.


Description:

Radio frequency treatment (RF) of the genicular nerves was found to be effective in a randomized controlled trial. Because of the blinding patients were allowed to continue pre-intervention pharmacological treatment, which may have interfered with the outcome. The short follow-up (12 weeks) does not allow drawing conclusion on the duration of the effect.

We aimed at assessing the pain reducing effect of RF of the genicular nerves and the duration of the effect.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date January 2016
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- patients suffering from pain caused by osteoarthrosis of the knee joint

- osteoarthrosis of the knee joint (grade 3-4 according to the Kellgren Lawrence classification)

- pain of moderate to severe intensity (VAS=5, on a 10-point scale) during >3 months

- pain resistant to conservative treatments

Exclusion Criteria:

- acute knee pain associated with radicular neuropathy or intermittent claudication, connective tissue diseases affecting the knee, serious neurologic or psychiatric disorders, mental deterioration impeding adequate communication or collaboration, injection with steroids or hyaluronic acids during the previous 3 months, anticoagulant medications, pacemakers, and prior electro-acupuncture treatment

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
RF treatment
the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
Radiation:
radiofrequency ablation

Device:
ultrasound


Locations

Country Name City State
Spain Hospital General de Jerez de la Frontera (Servicio Andaluz de Salud) Jerez de la Frontera Cadiz

Sponsors (2)

Lead Sponsor Collaborator
Hospital General de Jerez de la Frontera Ziekenhuis Oost-Limburg

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain reduction Pain intensity is measured using a 10-point VAS score 1, 6 and 12 months No
Secondary Global patient satisfaction Satisfaction is scored on a 4-point Likert scale: 1 (poor), 2 (average), 3 (good) and 4 (very good) 1,6 and 12 months No
Secondary Improvement of quality of life evaluated using the Western Ontario and MacMaster Universities Index of Osteoarthrosis (WOMAC) 1,6 and 12 months No
See also
  Status Clinical Trial Phase
Completed NCT04675034 - A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee Phase 2
Completed NCT04770428 - Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers Phase 1